Ping An Ventures, the direct investment arm of China’s Ping An Insurance, and Lilly Asia Ventures took part in the $100-million Series A financing round of Tmunity Therapeutics, the US-based immunotherapy developer that aims to fast-track the development of its T-cell-based personal cancer treatments.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
